Is GT Biopharma Stock a Good Investment?
GT Biopharma Investment Advice | GTBP |
- Examine GT Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GT Biopharma's leadership team and their track record. Good management can help GT Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact GT Biopharma's business and its evolving consumer preferences.
- Compare GT Biopharma's performance and market position to its competitors. Analyze how GT Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if GT Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GT Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GT Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GT Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine GT Biopharma Stock
Researching GT Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company shares are held by company insiders. The book value of GT Biopharma was currently reported as 5.41. The company recorded a loss per share of 7.39. GT Biopharma last dividend was issued on the 21st of August 2017. The entity had 1:30 split on the 5th of February 2024.
To determine if GT Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GT Biopharma's research are outlined below:
| GT Biopharma generated a negative expected return over the last 90 days | |
| GT Biopharma has high historical volatility and very poor performance | |
| GT Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (13.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (12.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 68.0% of the company shares are owned by institutional investors |
GT Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GT Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GT Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GT Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.23 M.Basic technical analysis of GTBP Stock
As of the 21st of March, GT Biopharma owns the Coefficient Of Variation of (2,618), information ratio of (0.03), and Market Risk Adjusted Performance of (0.52). GT Biopharma technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices.GT Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on GT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GT Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GT Biopharma's Outstanding Corporate Bonds
GT Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GT Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GTBP bonds can be classified according to their maturity, which is the date when GT Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand GT Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GT Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.52) | |||
| Mean Deviation | 3.81 | |||
| Coefficient Of Variation | (2,618) | |||
| Standard Deviation | 5.57 | |||
| Variance | 31.02 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | 0.2315 | |||
| Treynor Ratio | (0.53) | |||
| Maximum Drawdown | 29.58 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 8.25 | |||
| Skewness | 0.8173 | |||
| Kurtosis | 3.95 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.52) | |||
| Mean Deviation | 3.81 | |||
| Coefficient Of Variation | (2,618) | |||
| Standard Deviation | 5.57 | |||
| Variance | 31.02 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | 0.2315 | |||
| Treynor Ratio | (0.53) | |||
| Maximum Drawdown | 29.58 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 8.25 | |||
| Skewness | 0.8173 | |||
| Kurtosis | 3.95 |
Consider GT Biopharma's intraday indicators
GT Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GT Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GT Biopharma time-series forecasting models is one of many GT Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GT Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
GTBP Stock media impact
Far too much social signal, news, headlines, and media speculation about GT Biopharma that are available to investors today. That information is available publicly through GTBP media outlets and privately through word of mouth or via GTBP internal channels. However, regardless of the origin, that massive amount of GTBP data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GT Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GT Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GT Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GT Biopharma alpha.
GT Biopharma Corporate Management
| Michael Breen | Interim Chairman | Profile | |
| Manu Ohri | Chief Officer | Profile | |
| Jeffrey MD | Consulting Advisor | Profile | |
| Gregory MD | Chief RD | Profile | |
| MPH MBA | VP Management | Profile | |
| PharmD MBA | Chief Officer | Profile |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.